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Abstract Canalicular secretion of bile salts mediated by
the bile salt export pump Bsep constitutes the major driving
force for the generation of bile flow. Bsep is a member of
the B-family of the super family of ATP-binding cassette
transporters and is classified as ABCB11. Bsep has a
narrow substrate specificity, which is largely restricted to
bile salts. Bsep is extensively regulated at the transcrip-
tional and posttranscriptional level, which directly modu-
lates canalicular bile formation. Pathophysiological
alterations of Bsep by either inherited mutations or acquired
processes such as inhibition by drugs or disease-related
down regulation may lead to a wide spectrum of mild to
severe forms of liver disease. Furthermore, many genetic
variants of Bsep are known, some of which potentially
render individuals susceptible to acquired forms of liver
disease.
Keywords Bile formation . Bile acid transport . ATP-binding
cassette transporter . Mutation . Polymorphism
Introduction
Bile formation is one of the key functions of mammalian
liver. It involves vectorial secretion of bile acids and other
cholephilic compounds across hepatocytes from the sinu-
soidal blood plasma into bile canaliculi [50, 61, 78, 91]
(Fig. 1). Thereby, bile acids or bile salts are concentrated
more than 500-fold in bile as compared to blood plasma.
This concentrative process is dependent on ATP [87] and
mainly driven by the canalicular bile salt export pump
BSEP [61]. BSEP is a member of the B-family of the ATB-
binding cassette (ABC) superfamily of transporters and is
classified as ABCB11.
In 1995, a close relative to MDR1 (ABCB1 or P-
glycoprotein) was identified in pig and was named as the
sister of P-glycoprotein (spgp) [14]. In a panel of mRNAs
from different rat tissues, only the liver was positive by
Northern blotting. Based on the hypothesis that the canalic-
ular bile salt export system should be a member of the ABC-
transporter superfamily and predominantly, if not exclusively
expressed in the liver, the rat isoform of spgp was cloned from
liver. After its expression in insect Sf9 cells with the
baculovirus system, it could be demonstrated that spgp
represents an ATP-dependent bile salt transporter [33]. Based
on its function, spgp was renamed as “bile salt export pump”
or “Bsep”. Positional cloning of the defective gene in
patients with progressive familial intrahepatic cholestasis
type 2 (PFIC2) led to the identification of the human BSEP
gene [88], indicating that PFIC2 was actually a BSEP
deficiency syndrome [78]. The selective absence of bile salts
in the bile of all PFIC2 patients further confirmed the bile
salt transport function of BSEP [45]. Bsep is evolutionary
relatively old, and a Bsep orthologue is already present in
skate (Raja erinacea) liver [10]. Furthermore, partial Bsep
sequences have been described in the teleost winter flounder
(Pseudopleuronectes americanus) [14]. Of note, ATP-depen-
dent bile salt transport activity has also been demonstrated in
plant vacuoles [42] and in yeast, where the responsible
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transport protein (BAT1) is also a member of the ABC-
transporter superfamily [74].
Functional characteristics
The BSEP gene is located on chromosomes 2q24–31 [88].
Its 28 exons encode a protein of 1,321 amino acids [9, 72].
Rat and mouse Bsep consist of 1,321 amino acids and
exhibit molecular weights of 160 kDa [33, 35, 54, 69].
Based on comparison of the molecular weight of rat Bsep
expressed in Sf9 cells in comparison to rat canalicular
membrane vesicles, it is very likely that Bsep is a
glycoprotein [33]. Extensive functional comparison in
isolated rat canalicular plasma membrane vesicles and in
Sf 9 cell vesicles revealed similar kinetic properties of rat
Bsep with Km values of 2.1 μM for taurocholate, 3.8 μM
for glycocholate, 3.6 μM for taurochenodeoxycholate, and
6.2 μM for tauroursodeoxycholate [86]. These findings
indicate that expression in the Sf 9 cell systems is suitable
for functional characterization of various Bsep orthologues
from different species. In fact, comparison of the intrinsic
clearances of mouse, rat, and human Bsep/BSEP revealed
the same rank order of transporter preferences for different
bile salts and comparable Km values [72]. These close
functional relationships between Bsep of different species
are paralleled by amino acid sequence similarities of more
than 80%, indicating that functional studies with rat Bsep in
isolated canalicular liver plasma membrane vesicles can be
extrapolated to human BSEP. In rats, the specificity of Bsep
is restricted to monovalent bile salts, whereas no transport
of taurolithosulfocholate, leukotriene C4, DNP-SG, estra-
diol-17β-glucuronide, or GSSG was observed [86]. Recent-
ly, rat and human Bsep/BSEP were compared after
expression in HEK293 cells and were found to have
qualitative comparable transport properties with one excep-
tion: Human BSEP transported taurolithocholate 3-sulfate
significantly, whereas virtually no transport was observed
with rat Bsep [38]. This difference may reflect the fact that
the human bile salt pool contains higher amounts of
taurolithocholate 3-sulfate than the rodent bile salt pool.
Despite the close structural relationship between bile salts
to cholesterol, rat Bsep seems not to be able to transport
sitosterol [2]. Nevertheless, the substrate specificity of
Bsep/BSEP seems not to be entirely restricted to bile salts
since transfection of the ovary cancer cell line SKOV3 with
rat Bsep induced a slight resistance to taxol [15]. In
addition, mouse Bsep expressed in LLC-PK1 cells has been
shown to mediate the transport of vinblastine and the
fluorescent Mdr1 substrate calcein AM [54]. Interestingly,
in vesicles isolated from transfected HEK 293 cells, ATP-
dependent pravastatin transport could be demonstrated for
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Fig. 1 Principle mechanisms of bile formation. Bile salts are taken up
into hepatocytes in a sodium-dependent manner by the sodium-
taurocholate transporting polypeptide (NTCP) and, to a lesser extent,
in a sodium-independent manner by the organic anion transporting
polypeptides (OATPs) [61]. Bile salts are secreted across the
canalicular plasma membrane by the bile salt export pump (BSEP),
from where they promote in concert with the multidrug-resistance
protein 3 (MDR3) the release of phospholipids from the canalicular
plasma membrane (see article by Oude Elferink in this issue).
Phospholipids form together with bile salt-mixed micelles, which act
as a vehicle for cholesterol that is exported into the canaliculus by
ABCG5/G8 (see article by Patel in this issue). In addition, multidrug
resistance protein 2 (MRP2) and breast cancer resistance protein
(ABCG2) mediate canalicular secretion of organic anions and divalent
bile salts (see articles by Keppler and Sugiyama, respectively, in this
issue). The basolateral exporters MRP3 and MRP4 may act as salvage
systems to lower cytoplasmic levels of potentially hepatotoxic
compounds (see article by Borst in this issue)
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both rat Bsep and human BSEP [40]. Hence, although
monovalent bile salts represent the predominant transport
substrate class for all Bsep isoforms, some additional
compounds may also be transported by Bsep/BSEP.
Nevertheless, the fact that the absence of functional BSEP
in the canalicular membrane due to mutations in the
BSEP gene leads to severe forms of intrahepatic cholesta-
sis in childhood and to bile salt levels <1% of normal in
bile supports the concept that the major physiological role
of the bile salt export pump is ATP-dependent bile salt
transport [45].
Tissue distribution
The partial sequence of Bsep from pigs was used by Childs
and coworkers to determine its tissue distribution by
Northern blotting. These data revealed a predominant, if
not exclusive, expression of pig Bsep in the liver [14]. This
tissue distribution was confirmed after a full-length se-
quencing of Bsep in the rat [33] and in mouse [35, 54].
However, using a PCR-based approach, Bsep mRNA was
also identified in brain cortex and small and large intestine
in the rat [90]. Based on a real-time PCR approach,
expression of BSEP was not only found in human liver
but also at very high levels in human testis, an organ which
had not been previously investigated for BSEP expression
[53]. The same study detected some BSEP mRNA also in
several other tissues. The observed predominant expression
of Bsep in the liver is preserved during evolution since in
the primitive elasmobranch vertebrate, little skate, Bsep is
exclusively expressed in the liver [10].
Ontogenesis and regulation
Ontogenesis of Bsep has been most extensively studied in
rat liver. Bsep mRNA could be detected at day 15 in
developing mouse liver [54] and, although at low levels, at
embryonic day 20 in rat liver [30, 89, 104]. In rats, positive
canalicular protein expression is observed at low levels at
embryonic day 20. After embryonic day 20, the expression
of rat Bsep at the protein and mRNA levels rapidly
increases up to almost adult levels within the first week
after birth [30, 89, 104]. This sequence of expression
coincides well with the development of the major bile salt
uptake system Ntcp in rat liver as well as with the
development of the enterohepatic circulation of bile salts
[30]. In humans, the BSEP gene is expressed at mid-
gestation at mRNA levels much lower than in the adult
liver [13]. Immunohistochemical analysis demonstrated
BSEP expression in the fetal liver both at the bile canaliculi
and within hepatocytes.
Regulation of Bsep occurs at two main levels: first, at
the transcriptional level and, second, at the posttranscrip-
tional level by insertion and retrieval of Bsep into the
canalicular plasma membrane and/or posttranslational pro-
tein modifications. The latter two mechanisms can act at
very short-time scales, whereas regulation at the transcrip-
tional level has a more long-term impact.
Transcriptional regulation of Bsep The predominant tran-
scription factor involved in the transcriptional regulation
of Bsep expression is the farnesoid X receptor (FXR) [23,
50]. This transcription factor acts as an intracellular bile
salt sensor in hepatocytes and, upon activation by bile
salts, binds as a heterodimer with retinoid X receptor
(RXR) to the Bsep promoter. This leads to an upregula-
tion of Bsep expression and consequently to increased
canalicular bile salt secretion [3, 32]. These data are
supported by a reduced expression of Bsep in mice
lacking the gene for FXR [85]. This regulatory mecha-
nism seems to be more strongly affected by transhepato-
cellular bile salt flux than by steady-state bile salt levels
[102]. Since intracellular bile salts are elevated in
cholestatic liver disease, this regulatory pathway repre-
sents an important protective mechanism for hepatocytes
[23]. Recently, it has been shown that the vitamin D
receptor (VDR) directly interacts with FXR and, upon
binding of vitamin D3, inhibits FXR-mediated trans-
activation of BSEP [41]. In primary cultured rat hepato-
cytes, mRNA and Bsep protein levels are partially
maintained for approximately 72 h of culture time [82].
Interestingly, hyperosmolarity of the culture medium leads
to upregulation and hypoosmolarity to downregulation of
Bsep mRNA expression [100]. Furthermore, maintenance
of Bsep mRNA expression was reported to be critically
dependent on the presence of dexamethasone in the
culture medium [100]. However, in other studies using
sandwich cultured primary rat hepatocytes, the expression
of Bsep on both the mRNA and protein levels was less
sensitive to the presence of dexamethasone [57, 92],
although very low dexamethasone concentration influ-
enced Bsep expression levels also in primary hepatocytes
cultured in a collagen-sandwich configuration [92]. Taken
together, these results indicate that not only the bile acid
sensor FXR is crucial for the control of Bsep expression,
but more complex regulatory cascades involving for
example steroid receptors need to be considered as well.
This is supported by the observation that patients with
biliary atresia improve their bile flow rate after surgery
with high-dose steroid treatment [64].
Short-term posttranscriptional regulation of Bsep There is
considerable evidence from animal models that the cana-
licular localization of Bsep can be regulated by endo- and
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exocytotic mechanisms [4, 96]. Studies in isolated perfused
rat livers showed a stimulation of biliary excretion of bile
salts concomitant with a stimulation of vesicular transport
processes in hepatocytes [36]. Similar experiments in
isolated rat hepatocyte couplets resulted in an enhanced
secretion of a fluorescent bile acid derivative into the
canalicular vacuole [8]. This stimulation of bile salt
secretion is independent from protein synthesis but sensi-
tive to the microtubule disrupting agent colchicine, suggest-
ing the presence of an intracellular regulatory pool of Bsep
transporters. Treatment of rats with intravenous taurochcho-
late or dibutyryl cAMP resulted in a fast increase in
functional Bsep insertion into canalicular plasma mem-
branes [31]. Inhibition of this process by colchicine
confirmed the postulated presence of an intracellular
vesicular pool of Bsep, which upon stimulation is incorpo-
rated into the canalicular plasma membrane in a microtu-
bule-dependent process. In addition, cAMP-dependent
Bsep incorporation into the canalicular plasma membrane
was inhibited by wortmannin indicating an important role
of PI 3-kinase [66]. These regulatory mechanisms are
independent from protein biosynthesis and hence relate to
posttranscriptional events. In isolated rat canalicular plasma
membrane vesicles, products of PI 3-kinase action exerted a
direct effect on the transport activity of Bsep, indicating
that PI 3-kinase modulates bile salt transport activity both
by Bsep density and Bsep activity in the canalicular plasma
membrane [65]. Biosynthetic studies indicate a direct
targeting of Bsep from the Golgi to the canalicular plasma
membrane. Furthermore, treating rats simultaneously with
cAMP and with taurocholate resulted in additive incorpo-
ration of Bsep into the canalicular membrane to levels
higher than with a single modulator. Based on all these
observations, it has been postulated that two separate
intracellular pools exist within hepatocytes, from which
Bsep can be recruited and inserted into the canalicular
plasma membrane under the conditions of increased bile
flow rates [47]. In addition to these pathways, the mitogen-
activated kinase cascades are also involved in the posttran-
scriptional regulation of Bsep expression: Induction of
choleresis by tauroursodeoxycholic acid or alteration of bile
flow by anisosomolarity leads to canalicular insertion/
retrieval of Bsep, a process that is critically dependent on
mitogen-activated kinases [83]. In addition, studies in
polarized cell lines expressing Bsep revealed that HAX-1
and myosin II regulatory light chain are required for the
trafficking of Bsep to the apical membrane as well as in the
regulation of its abundance in the apical plasma membrane
of MDCK cells [12, 73]. Studies in the polarized hepatic
WIF-B9 cell line indicated that Bsep undergoes a constitu-
tive cycling between a rab11 positive compartment and the
canalicular plasma membrane domain [95]. Bsep and,
hence, the capacity of canalicuar bile salt secretion may
be regulated not only via carrier density in the canalicular
plasma membrane but also by posttranslational modifica-
tions of the Bsep protein. Mouse Bsep, if coexpressed with
the α-isoform of protein kinase C in Sf 9 cells, is
phosphorylated, which could affect the functional proper-
ties of Bsep [69, 71]. Posttranslational processes occur on
short-time scales may be needed to adapt canalicular bile
salt secretion to a short-term increase in hepatocellular bile
salt load, such as, for example, in a postprandial state. In
contrast, the half-life of Bsep in rats is 4 to 6 days, which is
in line with the half-life of other rat hepatocellular plasma
membrane proteins [48]. To our knowledge, factors
regulating the half-life of Bsep have not yet been
investigated. Such events may, however, turn out to be
important in chronic alterations of liver functions, such as
various forms of liver disease.
Pathophysiological consequences of altered Bsep
function and expression
Inhibition of Bsep/BSEP leads to a reduced bile salt
secretion and decreased bile flow, a process called
cholestasis. This has been shown in the perfused rat liver,
for example, for cyclosporine A [6]. After the cloning of rat
Bsep, it was possible to directly test the inhibition of Bsep
expressed in Sf 9 cells in the absence of other organic anion
transporters. These studies showed that cyclosporine A as
well as glybenclamide, rifampicin, and rifamycin are
competitive inhibitors of Bsep [86]. The same drugs also
inhibit human BSEP [9, 72]. Other drugs that have been
shown to inhibit BSEP are bosentan [25], troglitazone [29],
and fluvastatin (C. Lang, Y. Meier, and C. Pauli-Magnus,
submitted for publication). Such drugs may, in susceptible
humans, cause acquired cholestasis, which rapidly resolves
after the withdrawal of the drug. Alteration of Bsep-
mediated bile salt secretion can also be caused indirectly.
For example, the Bsep inhibitor bosentan leads to a
hypercholeresis in rats, which depends on the canalicular
presence of functional Mrp2 [28]. This canalicular hyper-
choleresis may lower the bile salt concentration in the
canalicular lumen and consequently reduce canalicular
lipid secretion [28]. Such a mechanism could in turn lead,
via secondary inhibition of Bsep, to the observed accumu-
lation of serum bile acids in rats after administration of
bosentan [25, 60]. Studies with mouse Bsep demonstrated
that some drugs inhibit not only the transport activity of
Bsep but also its ATPase activity [69]. Since the
substrate binding site(s) of the various Bsep isoforms is
unknown at present, it cannot be excluded that inhibitory
drugs are also potential transport substrates of Bsep.
Very interestingly, estradiol-17β-glucuronide, a cholestat-
614 Pflugers Arch - Eur J Physiol (2007) 453:611–620
ic metabolite of estrogen, requires coexpression of Mrps
for inhibition of Bsep [1, 86]. This has been interpreted
as so-called trans-inhibition since estradiol-17β-glucucro-
nide needs to be transported into the canalicular lumen
before it can exert its cholestatic action on Bsep. Most
importantly, this result has been confirmed for proges-
terone-sulfate, a key metabolite that increases during
pregnancy [93].
Although inhibition of Bsep by drugs and other
substances is rapid and reversible, other pathophysiological
situations are associated with more pronounced effects on
Bsep expression. Sepsis in patients with gram-negative
infections may be associated with cholestasis [67]. The
causative agent for induction is the endotoxin lipopolysac-
charide secreted by gram-negative bacteria. In experimental
septic models, Bsep mRNA and protein levels were
reduced [55, 94]. In addition, such models of sepsis have
provided evidence for a relocation of canalicular Bsep to a
percicanalicular vesicular compartment [7, 103]. These
effects on Bsep expression could be prevented with the
osmolyte taurine [68]. Treatment of human liver slices with
lipopolysaccharide also induced the downregulation of
BSEP at the protein level, suggesting similar mechanisms
in human liver as in animal models [22].
Obstructive cholestasis or cholestasis induced by ethi-
nylestradiol treatment of rats leads to a modest reduction in
the expression of Bsep in the canalicular membrane [55]
and thus resembles the moderate downregulation of Bsep in
primary cultured rat hepatocytes [82]. In the rat model of
cholestasis associated with pregnancy (treatment of rats
with estradiol), a relocation of Bsep into subapical vesicles
is observed [18]. If these rats are treated with 6-ethyl
chenodeoxycholate, a potent ligand for FXR, Bsep is
induced and the cholestasis induced by estradiol is reversed
[27]. And finally, treatment of rats with the cholestatic bile
acids lithocholate or taurolithocholate leads to a retrieval of
Bsep from the canalicular plasma membrane [19], which
can be prevented by the administration of cAMP [19],
silibinin [17], or tauroursodeoxy cholic acid [21].
In patients with obstructive cholestasis who underwent
biliary drainage, BSEP mRNA levels were reduced in
individuals with poor drainage as compared to controls.
Additionally, BSEP staining appeared fuzzy, indicating
altered expression as a consequence of cholestasis [84].
Another cholestatic liver disease is primary biliary cirrho-
sis. In such patients, the expression of BSEP is preserved in
contrast to the basolateral uptake systems [105, 106].
Patients with inflammation-induced icteric cholestasis due
to alcoholic hepatitis have a reduced expression of BSEP
mRNA and protein [106]. Frequently, cholestatic liver
disease is treated with ursodeoxycholic acid [5, 79]. In a
recent study, it was observed that treatment of patients with
ursodeoxycholic acid leads to a stimulation of BSEP
expression [59]. Additionally, after liver transplantation,
the bile flow rate is initially low and recovers with time.
This recovery of bile flow rate is paralleled by an increased
expression of BSEP mRNA in liver biopsies from trans-
planted livers [34].
Genetics
Mutations in canalicular transporter genes and in particular
in the BSEP gene that lead to hereditary forms of liver
disease are well known. The BSEP deficiency syndrome is
caused by mutations in the BSEP gene and leads to
functional defects of BSEP-mediated canalicular bile salt
secretion [78]. Depending on the clinical course of this
syndrome, two different clinical entities of the BSEP
deficiency syndrome are known: a mild form also called
benign recurrent intrahepatic cholestasis type 2 (BRIC2)
and a severe form also called progressive familial intra-
hepatic cholestasis type 2 (PFIC2). These two diseases
represent a heterogeneous group of cholestatic conditions,
and BRIC 2 may develop into PFIC2 [51, 78]. So far, more
than 30 mutations in the BSEP gene have been identified in
patients with BSEP deficiency syndrome [78] (Fig. 2). The
majority of these mutations affect evolutionary conserved
amino acid residues, and the affected amino acids tend to be
located in the large cytoplasmic loops of BSEP. In many
patients with severe BSEP deficiency syndrome, BSEP
staining was absent on liver sections [45, 46]. Direct
investigation of the functional consequences of the BSEP
mutations in human liver is impossible. Therefore, studies
using heterologous expression systems of mutated forms of
BSEP were used to subsidize for this lack of in vivo data.
Expression of various BSEP mutations affecting conserved
amino acids in a rat or mouse background in polarized cells
such as MDCK or HepG2 cells has resulted in defects of
apical trafficking and/or functional impairment of BSEP as
well as in temperature-sensitive, unstable forms of BSEP
[81, 97]. It should, however, be noted that such studies on
the functional impact of the human mutations based on
heterologous expression systems may lead to conflicting
results suggesting species-specific effects on transport
function [81, 97]. Therefore, directly testing the human
mutated forms of BSEP in vivo seems to be an important
prerequisite to obtain insights into the functional conse-
quences of BSEP mutations [37, 70].
Although inherited mutations in the BSEP gene are very
rare [75, 77], acquired forms of cholestasis such as, for
example, primary biliary cirrhosis, primary sclerosing
cholangitis, cholestasis associated with pregnancy, or
drug-induced cholestasis are more frequent [62, 77]. A
recent genetic screen of patients identified three non-
synonymous ABCB11 variants to be specifically associated
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with primary biliary cirrhosis and primary sclerosing
cholangitis [76]. In cholestasis associated with pregnancy,
the situation seems to be controversial [24, 78]. Conse-
quences of such variants potentially include altered expres-
sion and or altered function of BSEP.
Cholestasis induced by BSEP inhibition, for example, by
drugs, is a rare event observed in patients. Hence, there need
to be underlying mechanisms rendering such patients
susceptible to BSEP inhibition. A strong candidate is the
genetic background. Recently, the variation of BSEP protein
expression levels was studied in 110 healthy liver specimens
by Western blotting [63]. BSEP expression levels of these
individuals were found to display a unimodal distribution
and showed no correlation with, for example, sex or
medication. Importantly, 17% of the individuals were found
to have a low or very low expression level. In these
individuals, low BSEP expression level was found to be
associated with the nonsynonymous 1457C allele (444A) of
ABCB11. Individuals with low or very low expression
levels of BSEP could be at risk of developing acquired
forms of cholestasis, for example, by drugs or pregnancy.
Mice with genetically altered Bsep expression
In contrast to humans, functional inactivation of the Bsep
gene (also called sister of P-glycoprotein gene, spgp) does
not lead to a severe, progressive cholestasis in mice [99].
Although the knockout animals are viable and fertile, they
present with mild growth retardation. Knockout animals
have no abnormalities in their serum liver parameters. Their
bile flow rate is slightly but not significantly lower in
comparison to controls, but the total bile salt output into
bile is massively reduced and their liver bile salt concen-
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Fig. 2 Putative secondary structure of Bsep (NT-005403) generated
with the TOPO program (http://www.sacs.ucsf.edu/TOPO-run/wtopo.pl).
Walker A motif, family signature, and Walker B motif [20] are shown in
orange. Genetic variants and mutations (taken from [51, 78]) are
represented as green for single nucleotide polymorphisms (SNP), red for
mutations identified in patients with progressive familial intrahepatic
cholestasis type 2 (PFIC1), and blue for mutations identified in patients
with benign recurrent intrahepatic cholestasis type 2 (BRIC2). purple
E297G was found in PFIC2 and BRIC2 patients, respectively. Amino
acids highlighted in cyan were associated acquired forms of cholestasis
including intrahepatic cholestasis of pregnancy, primary sclerosing
cholangitis, and primary biliary cirrhosis. (*) The mutation V284L was
found in a patient with PFIC2, whereas the SNP V284A occurs in healthy
individuals
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trations are increased accordingly. Biliary secretion of
cholate and its conjugates is 6% of normal, supporting the
key role of Bsep in canalicular taurocholate secretion. Most
interestingly, these knockout mice secrete a novel tetrahy-
droxylated bile acid into bile [80]. The Bsep knockout
animals have substantial increases of malondialdehyde
levels in brain and heart, indicating an increased lipid
peroxidation as a consequence of elevated serum bile acid
levels [56]. If Bsep knockout animals are fed with a diet
containing cholate, they become severely cholestatic and
have a high mortality rate, which is more pronounced in
males than females [98]. Unexpectedly, cholate-fed knock-
out mice secrete significant amounts of cholate conjugate
into bile, indicating a salvage transport system for canalic-
ular bile salt secretion. Comparative analysis of gene
expression profiles in control and knockout-mice after
cholate feeding revealed a striking upregulation of Mdr1a
[98]. This observation may indicate that mouse Mdr1a
could act as a salvage transporter for bile salts in conditions
of high intracellular bile salt concentration. Transport
studies using canalicular plasma membrane vesicles from
Bsep knockout animals revealed a residual ATP-dependent
transport activity for taurocholate [52]. Plasma membrane
vesicles isolated from a drug-resistant Chinese hamster
ovary cell line expressing high levels (about 15% of total
plasma membrane proteins) of class I P-glycoprotein also
exhibit ATP-dependent bile salt transport, albeit with lower
affinity than Bsep [52]. Hence, Mdr1 may act as a salvage
system for bile salts in case of nonfunctional or impaired
Bsep. Since the affinity of Mdr1 for bile salts is much
lower, intracellular bile salts may rise to toxic levels in
hepatocytes and cause liver injury (see article by V. Ling,
this issue). The situation in patients with PFIC2 may differ
to some extent from the knockout animals since analysis of
four PFIC2 patients showed no significant upregulation of
MDR1 mRNA [46].
Overexpression of Bsep in the liver transgenic animals
leads to an increased biliary bile salt output concomitant
with an increase in bile flow rate and biliary lipid secretion
[26]. Fecal loss of bile salts is normal in these animals. If
these mice are fed a lithogenic diet, they have a markedly
reduced hepatic steatosis in comparison to controls. These
findings highlight the role of Bsep in the maintenance of
hepatocellular lipid homeostasis.
Outlook
The gene for the bile salt export pump Bsep was initially
identified as a close relative of the gene encoding P-
glycoprotein. Bsep was subsequently shown to be an ATP-
driven bile salt pump located to the canalicular plasma
membrane of hepatocytes. In this strategic position, Bsep is
a key transporter involved in canalicular bile formation and
constitutes the main driving force for enterohepatic circu-
lation of bile salts. The regulation of Bsep is set up such
that bile salt concentrations in hepatocytes are kept constant
at low levels. On the basis that elevated bile salt concen-
trations are toxic to hepatocytes [49], Bsep may act as a
“vacuum cleaner” [39] for bile salts in hepatocytes. Proper
function of Bsep is critical for maintaining bile salt
concentration in systemic circulation in a tight range at
low levels. In the light of recent findings that bile salt-
mediated FXR signaling controls liver regeneration and
may even control liver size [44], Bsep may move up to a
key protein controlling many vital processes in liver.
Furthermore, evidence that the bile acid sensor FXR is
controlling glucose and lipid metabolism is rapidly accu-
mulating [11, 16, 58]. Since FXR requires bile salt binding
to act to control expression target genes, Bsep may, by
controlling bile salt concentration in systemic circulation,
become an important control element in body energy and
lipid homeostasis. And finally, bile salts have recently been
shown to control energy expenditure by controlling
intracellular thyroid hormone action by binding to the G
protein-coupled receptor TGR5 [43, 101].
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